A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Protocol No
SWOG-LUNGMAP-S1800A
Principal Investigator
Smitha Menon
Phase
II
Summary
This study is being done to answer the following question: Can we lower the chance of your lung cancer growing or spreading by combining two drugs that work with your immune system to fight your cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your lung cancer. The usual approach is defined as care most people get for their lung cancer.
Description
Targeted Treatment (ramucirumab plus pembrolizumab) for Advanced Non-Small Cell Lung Cancer
Participating Institutions
Froedtert Hospital
Froedtert West Bend Hospital
Froedtert Menomonee Falls Hospital
Status
OPEN TO ACCRUAL
Share This: